Trial · NCT07906821
Ultrasound-guided Microwave Ablation of Benign Thyroid Nodules
NCT07906821, Not applicable, Recruiting, Chinese University of Hong Kong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ultrasound-guided Microwave Ablation of Benign Thyroid Nodules. Trials, record NCT07906821. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906821
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ultrasound-guided Microwave Ablation of Benign Thyroid Nodules
- NCT number
- NCT07906821
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Chinese University of Hong Kong
- Conditions
- Thyroid Nodule (Diagnosis)
- Interventions
- ultrasound-guided percutaneous microwave ablation (MWA)
- First posted
- 2026-10-30
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Thyroid nodule volume reduction rate (VRR) at 3 months post operation | Baseline and 3 months post operation | Thyroid nodule volume is measured via ultrasound and calculated using the ellipsoid formula (length × width × depth × π/6). Changes in nodule volume are expressed as the VRR (%) calculated using the following formula: (Baseline volume - nodule volume at 3 months post operation) × 100/ Baseline volume. This is the percentage measurement of how much a nodule has shrunk compared to its size before the procedure. A positive thyroid nodule volume reduction rate (VRR) means that the physical size (volume) of a thyroid nodule has successfully decreased following the operation. A negative thyroid nodule volume reduction rate (VRR) means that the size or volume of a thyroid nodule increased rather than shrank after a monitoring period. |
| Secondary | Procedure time of microwave ablation | At the time of operation (Day 0) | Procedure time is defined as the duration from the insertion of the microwave ablation antenna into the patient until the removal of the antenna, measured in minutes. |
| Secondary | Pain intensity as assessed by the Visual Analog Scale (VAS) | Day 0 | The Visual Analog Scale (VAS) is a self-reported instrument used to measure subjective pain intensity after the operation. The total score ranges from 0 to 10, where a score of 0 represents "no pain" and a score of 10 represents "the worst imaginable pain". Higher scores indicate greater pain severity. Maximum pain score recorded on the day of the microwave ablation procedure (Day 0) |
| Secondary | Overall Satisfaction Score of the operation at 3 years post operation | 3 years post operation | Overall satisfaction of the operation assessed using a Visual Analog Scale (VAS). Scores range from 0 to 10, where 0 indicates "completely dissatisfied" and 10 indicates "completely satisfied". A higher score represents a better outcome. |
| Secondary | Change From Baseline in Visual Analog Scale (VAS) Score for Pressure Symptoms at 3 years post operation | Baseline and 3 years post operation | The Visual Analog Scale (VAS) is used to self-report the severity of pressure symptoms. The scale ranges from 0 to 10, where 0 indicates "no symptoms" and 10 indicates "the most severe symptoms imaginable". Higher scores represent worse outcomes. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906821
GET https://conductscience.org/api/trials/v1/NCT07906821/registered